ChemoCentryx, Inc.

2015 Q1 Form 10-K Financial Statement

#000119312515090602 Filed on March 13, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2013 Q4 2013 Q3

Balance Sheet

Concept 2015 Q1 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.80M $133.3M $124.5M
YoY Change -43.59% 29.8% -0.8%
Cash & Equivalents $25.44M $10.26M $22.32M
Short-Term Investments $49.40M $123.1M $102.2M
Other Short-Term Assets $1.200M $600.0K $600.0K
YoY Change 9.09% 0.0% -25.0%
Inventory
Prepaid Expenses
Receivables $400.0K $500.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $76.05M $134.3M $125.6M
YoY Change -43.11% 28.54% -0.69%
LONG-TERM ASSETS
Property, Plant & Equipment $1.181M $1.399M $1.440M
YoY Change -7.59% -1.55% 20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $29.90M $16.60M $32.70M
YoY Change 221.51% 1.84% 1067.86%
Other Assets $175.0K $160.0K $160.0K
YoY Change 9.38% 0.0% -20.0%
Total Long-Term Assets $31.28M $18.12M $34.33M
YoY Change 190.36% 1.55% 737.34%
TOTAL ASSETS
Total Short-Term Assets $76.05M $134.3M $125.6M
Total Long-Term Assets $31.28M $18.12M $34.33M
Total Assets $107.3M $152.4M $160.0M
YoY Change -25.7% 24.61% 22.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $809.0K $909.0K $692.0K
YoY Change 13.94% 21.2% 15.33%
Accrued Expenses $6.937M $5.649M $5.004M
YoY Change 12.12% -9.86% -16.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $314.0K $400.0K
YoY Change -37.2% -20.0%
Total Short-Term Liabilities $7.746M $6.872M $6.485M
YoY Change 9.39% -39.19% -44.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $16.00K $100.0K
YoY Change -96.0% -80.0%
Other Long-Term Liabilities $181.0K $226.0K $222.0K
YoY Change -7.18% -24.16% -55.6%
Total Long-Term Liabilities $181.0K $242.0K $222.0K
YoY Change -7.18% -18.79% -77.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.746M $6.872M $6.485M
Total Long-Term Liabilities $181.0K $242.0K $222.0K
Total Liabilities $7.927M $7.114M $6.769M
YoY Change 8.95% -40.6% -46.28%
SHAREHOLDERS EQUITY
Retained Earnings -$231.8M -$172.9M -$163.3M
YoY Change 25.7% 28.82%
Common Stock $331.2M $43.00K $43.00K
YoY Change 770165.12% 19.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $99.41M $145.3M $153.2M
YoY Change
Total Liabilities & Shareholders Equity $107.3M $152.4M $160.0M
YoY Change -25.7% 24.61% 22.48%

Cashflow Statement

Concept 2015 Q1 2013 Q4 2013 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42888168 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.71
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2010Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
4000000
CY2012Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
20.00
CY2012Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
150000 shares
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43537104 shares
CY2014Q2 dei Entity Public Float
EntityPublicFloat
68500000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
75997000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40155000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
110346000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4592000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8460000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42888168 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
150000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2383920 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5301622 shares
CY2013Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
16000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
70964000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6866000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6872000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
40000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
909000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172862000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5649000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
145308000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
226000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
324000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152422000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
318103000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
399000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4956000
CY2013Q4 us-gaap Line Of Credit
LineOfCredit
300000
CY2013Q4 us-gaap Liabilities
Liabilities
7114000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1589000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
66000
CY2013Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
314000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10258000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1399000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
147828000
CY2013Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
16561000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
70964000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
596000
CY2013Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
393000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
5864000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8265000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
59592000
CY2013Q4 us-gaap Assets
Assets
152422000
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8212000
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
147788000
CY2013Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
123055000
CY2013Q4 us-gaap Cash
Cash
2000000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
134302000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
882000
CY2013Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2013Q4 ccxi Common Stock Issued Subject To Repurchase
CommonStockIssuedSubjectToRepurchase
0 shares
CY2013Q4 ccxi Deferred Tax Assets Amortization Of Deferred Non Qualified Stock Compensation
DeferredTaxAssetsAmortizationOfDeferredNonQualifiedStockCompensation
4226000
CY2013Q4 ccxi Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
400000
CY2013Q4 ccxi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
20.00
CY2013Q4 ccxi Assets Secured Under Credit Facility Carrying Amount
AssetsSecuredUnderCreditFacilityCarryingAmount
400000
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1700000 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
150000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 ccxi Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
3337000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43446096 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43446096 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.29
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3878010 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.91
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Investment
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2010735 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6831532 shares
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
89279000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7324000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8190000
CY2014Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-70000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
748000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219791000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
937000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7442000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
108606000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
185000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
250000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3933000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
315000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
915000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116981000
CY2014Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
328440000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
254000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5390000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
894000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8532000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3870863
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
74699000
CY2014Q4 us-gaap Assets
Assets
116981000
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
15922000
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
114537000
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
57282000
CY2014Q4 us-gaap Cash
Cash
200000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
181000
CY2014Q4 us-gaap Liabilities
Liabilities
8375000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1956000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
872000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16075000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1208000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4765642
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
114467000
CY2014Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
41263000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
89279000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
972000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
83000
CY2014Q4 us-gaap Available For Sale Securities And Held To Maturity Securities
AvailableForSaleSecuritiesAndHeldToMaturitySecurities
0
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
191800000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6712000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
74329000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
1419000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
191300000
CY2014Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2014Q4 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
3867834
CY2014Q4 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
4698749
CY2014Q4 ccxi Common Stock Issued Subject To Repurchase
CommonStockIssuedSubjectToRepurchase
0 shares
CY2014Q4 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
6647893 shares
CY2014Q4 ccxi Deferred Tax Assets Amortization Of Deferred Non Qualified Stock Compensation
DeferredTaxAssetsAmortizationOfDeferredNonQualifiedStockCompensation
6041000
CY2014Q4 ccxi Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
408000
CY2014Q4 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
3842220 shares
CY2014Q4 ccxi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
20.00
CY2014Q4 ccxi Percentage Of Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Settlement
PercentageOfIncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement
0.50 pure
CY2014Q4 ccxi Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
4982000
CY2014Q4 ccxi Equipment Financing Obligations
EquipmentFinancingObligations
0
CY2012Q1 ccxi Changed In Estimate Of Research And Development Term
ChangedInEstimateOfResearchAndDevelopmentTerm
P7Y2M
CY2012Q1 ccxi Warrant Contractual Term
WarrantContractualTerm
P10Y
CY2013 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
571000
CY2013 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
136600000
CY2013 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-763000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16700000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-34000
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2678000
CY2013 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
38000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-39115000
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-33318000
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0580 pure
CY2013 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
85000 shares
CY2013 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
0.00 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40916000 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.4310 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0050 pure
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.95
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0390 pure
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5474876 shares
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38635000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
442000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
881000
CY2013 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
6060000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
554000
CY2013 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
38000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-38673000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
501000
CY2013 us-gaap Interest Paid
InterestPaid
26000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6092000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6092000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3761000
CY2013 us-gaap Interest Expense
InterestExpense
59000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33541000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1798000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
942000
CY2013 us-gaap Depreciation
Depreciation
576000
CY2013 us-gaap Interest Expense Other
InterestExpenseOther
59000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
66784000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64365000
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
150000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-31668000
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
45175000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11634000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
159000
CY2013 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2678000
CY2013 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
100344000
CY2013 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5142000
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
312000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
6242000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5600000
CY2013 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-723000
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
517000
CY2013 ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
150000
CY2013 ccxi Stock Issued During Period Values Warrants Exercised
StockIssuedDuringPeriodValuesWarrantsExercised
312000
CY2013 ccxi Federal Research Tax Credit Extended Period
FederalResearchTaxCreditExtendedPeriod
P2Y
CY2013 ccxi Contract Revenue Upfront Payment And Milestone Payments Earned As Percentage Of Revenue
ContractRevenueUpfrontPaymentAndMilestonePaymentsEarnedAsPercentageOfRevenue
1.00 pure
CY2013 ccxi Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0110 pure
CY2013 ccxi Deferred Tax Asset Excess Tax Benefits
DeferredTaxAssetExcessTaxBenefits
3800000
CY2013 ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
-2065000
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.69
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
ChemoCentryx, Inc.
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Trading Symbol
TradingSymbol
CCXI
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2014 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Description of Business</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally administered chemokine-based therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company&#x2019;s principal operations are in the United States and it operates in one segment.</font></p> </div>
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-34315000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
548950 shares
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0580 pure
CY2014 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2011-03-31
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2487000 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2622135 shares
CY2014 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
150000 shares
CY2014 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
0.00 pure
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.</p> </div>
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43275000 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
The Company received a discounted lease rate during the first year of the agreement.
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3900 pure
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M23D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.69
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2123000
CY2014 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-110000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-47399000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47039000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
470000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M2D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.51
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001340652
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
CY2014 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.067 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0180 pure
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7134742 shares
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentration of Credit Risk</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company invests in a variety of financial instruments and, by its policy, limits the amount of credit exposure with any one issuer, industry or geographic area.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Accounts receivable are typically unsecured and are concentrated in the pharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies. At December&#xA0;31, 2014 and 2013, the Company had an accounts receivable balance of $0 and $0.4 million, respectively, which solely consisted of amounts due from Glaxo Group Limited (GSK) under its former collaboration agreement. The Company believes that the credit risks associated with GSK are not significant. During the three years ending December&#xA0;31, 2014, the Company has not written off any accounts receivable, and accordingly, does not have an allowance for doubtful accounts as of December&#xA0;31, 2014 and 2013. During the years ended December&#xA0;31, 2013 and 2012, 100% of the Company&#x2019;s total revenues were derived from&#xA0;contract revenue, up-front payments and development milestone payments earned under the Company&#x2019;s former collaboration with GSK.</font></p> </div>
CY2014 us-gaap Availableforsale Securities Gross Unrealized Gain Loss1
AvailableforsaleSecuritiesGrossUnrealizedGainLoss1
0
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
376000
CY2014 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
21000
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
408140 shares
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
330000
CY2014 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
100837000
CY2014 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-393000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18300000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
434000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
352000
CY2014 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2014 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-110000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-46929000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
494000
CY2014 us-gaap Interest Paid
InterestPaid
137000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7960000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7960000
CY2014 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2014 us-gaap Interest Expense
InterestExpense
24000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33815000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5817000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
993700
CY2014 us-gaap Depreciation
Depreciation
543000
CY2014 us-gaap Interest Expense Other
InterestExpenseOther
24000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1793000
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
254000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
38339000
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
47399000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13584000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-161000
CY2014 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2123000
CY2014 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
139528000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
8214000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1100000
CY2014 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2014 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1865000
CY2014 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P6Y8M1D
CY2014 ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
254000
CY2014 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
P5Y3M29D
CY2014 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice
8.28
CY2014 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized
0 shares
CY2014 ccxi Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0260 pure
CY2014 ccxi Expiration Date
ExpirationDate
2019-04
CY2014 ccxi State Operating Loss Carryforward Expiration Year
StateOperatingLossCarryforwardExpirationYear
2016
CY2014 ccxi Federal Research And Development Credits Expiration Year
FederalResearchAndDevelopmentCreditsExpirationYear
2019
CY2014 ccxi Initial Public Offering Completion Period
InitialPublicOfferingCompletionPeriod
2012-02
CY2014 ccxi Federal Operating Loss Carryforward Expiration Year
FederalOperatingLossCarryforwardExpirationYear
2025
CY2014 ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised
0 shares
CY2014 ccxi Deferred Tax Asset Excess Tax Benefits
DeferredTaxAssetExcessTaxBenefits
4200000
CY2014 ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
-2157000
CY2014 ccxi Available For Sale Securities Debt Maximum Maturities Period
AvailableForSaleSecuritiesDebtMaximumMaturitiesPeriod
Less than two years
CY2014 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice
7.92
CY2014 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Shares Authorized Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAuthorizedWeightedAverageExercisePrice
0
CY2014 ccxi Line Of Credit Facility Capacity Utilized
LineOfCreditFacilityCapacityUtilized
2200000
CY2014 ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Expired Or Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExpiredOrForfeited
548950 shares
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-32227000
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0583 pure
CY2012 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
0 shares
CY2012 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
0.00 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35407000 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3948 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0033 pure
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0069 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5594410 shares
CY2012 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
547000
CY2012 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
177566000
CY2012 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
649000
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15700000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-692000
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1935000
CY2012 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
10214000
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
971000
CY2012 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
33000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-39630000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39858000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-261000
CY2012 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
5419000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
472000
CY2012 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
33000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-39891000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
533000
CY2012 us-gaap Interest Paid
InterestPaid
50000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4812000
CY2012 us-gaap Stock Issued1
StockIssued1
10215000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4812000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4402000
CY2012 us-gaap Interest Expense
InterestExpense
794000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34569000
CY2012 us-gaap Interest Expense Debt
InterestExpenseDebt
711000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-31695000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
872000
CY2012 us-gaap Depreciation
Depreciation
592000
CY2012 us-gaap Interest Expense Other
InterestExpenseOther
83000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
57436000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
57017000
CY2012 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
141000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-56904000
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
45049000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10480000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
214000
CY2012 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
966000
CY2012 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
115552000
CY2012 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5582000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
4953000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000
CY2012 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1758000
CY2012 ccxi Reclassification Of Warrants Liability To Additional Paid In Capital Upon Conversion Of Convertible Note Upon Initial Public Offering
ReclassificationOfWarrantsLiabilityToAdditionalPaidInCapitalUponConversionOfConvertibleNoteUponInitialPublicOffering
1052000
CY2012 ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
141000
CY2012 ccxi Contract Revenue Upfront Payment And Milestone Payments Earned As Percentage Of Revenue
ContractRevenueUpfrontPaymentAndMilestonePaymentsEarnedAsPercentageOfRevenue
1.00 pure
CY2012 ccxi Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0137 pure
CY2012 ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
-2571000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2013Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1927000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-10193000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-11537000
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2013Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1886000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-9504000
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-12261000
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2013Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1522000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-9433000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-10941000
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2013Q4 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
725000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-9543000
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-12190000

Files In Submission

Name View Source Status
0001193125-15-090602-index-headers.html Edgar Link pending
0001193125-15-090602-index.html Edgar Link pending
0001193125-15-090602.txt Edgar Link pending
0001193125-15-090602-xbrl.zip Edgar Link pending
ccxi-20141231.xml Edgar Link completed
ccxi-20141231.xsd Edgar Link pending
ccxi-20141231_cal.xml Edgar Link unprocessable
ccxi-20141231_def.xml Edgar Link unprocessable
ccxi-20141231_lab.xml Edgar Link unprocessable
ccxi-20141231_pre.xml Edgar Link unprocessable
d835597d10k.htm Edgar Link pending
d835597dex211.htm Edgar Link pending
d835597dex231.htm Edgar Link pending
d835597dex311.htm Edgar Link pending
d835597dex312.htm Edgar Link pending
d835597dex321.htm Edgar Link pending
d835597dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g835597g57k74.jpg Edgar Link pending
g835597g92m62.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending